Balance Sheet
Cash Flow Statement
Capital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in IntangiblesChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Growth Metrics
Income Statement
Others
Ratios

BeOne Medicines (BEIGF) Depreciation and Depletion (2016 - 2025)

Historic Depreciation and Depletion for BeOne Medicines (BEIGF) over the last 11 years, with Q3 2025 value amounting to $35.7 million.

  • BeOne Medicines' Depreciation and Depletion fell 4897.76% to $35.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $146.2 million, marking a year-over-year increase of 539.8%. This contributed to the annual value of $166.9 million for FY2024, which is 10754.14% up from last year.
  • As of Q3 2025, BeOne Medicines' Depreciation and Depletion stood at $35.7 million, which was down 4897.76% from $29.9 million recorded in Q2 2025.
  • In the past 5 years, BeOne Medicines' Depreciation and Depletion ranged from a high of $70.0 million in Q3 2024 and a low of $9.4 million during Q1 2021
  • Over the past 5 years, BeOne Medicines' median Depreciation and Depletion value was $19.2 million (recorded in 2023), while the average stood at $23.8 million.
  • In the last 5 years, BeOne Medicines' Depreciation and Depletion soared by 26393.31% in 2024 and then plummeted by 4897.76% in 2025.
  • Over the past 5 years, BeOne Medicines' Depreciation and Depletion (Quarter) stood at $12.3 million in 2021, then soared by 38.57% to $17.0 million in 2022, then grew by 22.38% to $20.9 million in 2023, then skyrocketed by 135.1% to $49.0 million in 2024, then fell by 27.15% to $35.7 million in 2025.
  • Its Depreciation and Depletion stands at $35.7 million for Q3 2025, versus $29.9 million for Q2 2025 and $31.6 million for Q1 2025.